一种细胞在药物分子筛选中的用途

By using the multiple myeloma cell line RPMI8226 as a drug screening model, the problems of TF-1 cell model dependence on exogenous cytokines and narrow response window in TL1A-related drug screening were solved, achieving efficient and intuitive drug screening results, which are suitable for the treatment of diseases related to the TL1A-DR3 signaling pathway.

CN120505394BActive Publication Date: 2026-07-17ALL INNOVATION (HANG ZHOU) PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
ALL INNOVATION (HANG ZHOU) PHARMACEUTICAL TECHNOLOGY CO LTD
Filing Date
2025-07-04
Publication Date
2026-07-17

Smart Images

  • Figure CN120505394B_ABST
    Figure CN120505394B_ABST
Patent Text Reader

Abstract

本发明涉及一种细胞在药物分子筛选中的用途、相应的药物筛选方法以及药物筛选体系。本发明首次发现，多发性骨髓瘤细胞系对TL1A刺激呈现显著的浓度依赖性细胞死亡反应，并且靶向TL1A的抑制性药物可显著抑制TL1A诱导的细胞Caspase3 / 7酶活性升高和 / 或细胞死亡，且这种抑制效应呈现明确的剂量‑效应关系，该发现表明，多发性骨髓瘤细胞系可作为理想的细胞模型用于靶向TL1A‑DR3的药物筛选，从而为TL1A‑DR3靶向药物的筛选、活性分析及作用机制研究提供了一种高效、直观且具有临床转化价值的工具，具有显著的科学意义和产业应用潜力。
Need to check novelty before this filing date? Find Prior Art